作者@article {Singhal1593 = {Singhal,普拉蒂and Lunia, Prajay and Salgia, Kapil and Syed, Iram}, title = {Incidence of cycloserine induced neurotoxicity in drug resistant TB patients attending a tertiary care hospital}, volume = {56}, number = {suppl 64}, elocation-id = {1593}, year = {2020}, doi = {10.1183/13993003.congress-2020.1593}, publisher = {European Respiratory Society}, abstract = {Introduction: Cycloserine is a 2nd line ATT group B drug (WHO) used in doses of 10-15 mg/kg. While cycloserine induced psychiatric effects are well known but neurotoxicity is not commonly diagnosed with few reported cases.Aim \& Objectives: To study incidence of Cycloserine induced neurotoxicity \& neuroimaging findings in patients of Drug Resistant TB.Method: Retrospective study of patients of drug Resistant TB (MDR, Pre XDR \& XDR TB) attending a tertiary care hospital over past 5 yrs was conducted. Of 93 patients, 89 were eligible for enrollment as received cycloserine as part of regimen as per standard recommendations.Results: 3/89 (3.37\%) patients (2 male, 1 female) between15-35 yrs developed neurotoxicity with neuroimaging changes in form of B/L symmetrical restricted diffusion in dentate nuclei. 2 patients were CNS MDR TB diagnosed on CSF pyrosequencing. Both developed worsening headache after Rx, I at 1 \& other 11 month of Rx. 3rd patient was diagnosed as MDR PTB on BAL TB culture \& DST. He developed seizure after 3 months of Rx. After cessation of cycloserine all patients has resolutions of symptoms early \& neuroimaging changes reversed on MRI (done 1 yr later) of stopping cycloserine.Conclusion: Our study suggests cycloserine induced neurotoxicity with neuroimaging changes is 3.37 \%. No correlation with duration of Rx noted. Identifying cycloserine as cause of neurotoxicity can be challenging due to concurrent administration of other drugs. Neuroimaging in such cases can help in confirming diagnosis of cycloserine neurotoxicity \& guide necessary changes to treatment to prevent morbidity \& mortality.FootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 1593.This abstract was presented at the 2020 ERS International Congress, in session {\textquotedblleft}Respiratory viruses in the "pre COVID-19" era{\textquotedblright}.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).}, issn = {0903-1936}, URL = {//www.qdcxjkg.com/content/56/suppl_64/1593}, eprint = {//www.qdcxjkg.com/content}, journal = {European Respiratory Journal} }